{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:06:38Z","timestamp":1792699598333,"version":"4.5.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s40262-025-01548-7","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T16:37:08Z","timestamp":1753115828000},"page":"1263-1282","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Clinical Pharmacokinetics and Pharmacodynamics of Remimazolam"],"prefix":"10.1007","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-3939-9935","authenticated-orcid":false,"given":"Bas T.","family":"de Jong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0340-3847","authenticated-orcid":false,"given":"Douglas J.","family":"Eleveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9375-7816","authenticated-orcid":false,"given":"Keira P.","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0421-536X","authenticated-orcid":false,"given":"Michel M. R. F.","family":"Struys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,21]]},"reference":[{"issue":"1","key":"1548_CR1","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/01.anes.0000267503.85085.c0","volume":"107","author":"GJ Kilpatrick","year":"2007","unstructured":"Kilpatrick GJ, McIntyre MS, Cox RF, Stafford JA, Pacofsky GJ, Lovell GG, et al. CNS 7056: a novel ultra-short-acting benzodiazepine. Anesthesiology. 2007;107(1):60\u20136.","journal-title":"Anesthesiology"},{"key":"1548_CR2","volume-title":"Rang and Dale\u2019s pharmacology","author":"HP Rang","year":"2007","unstructured":"Rang HP, Dale MM, Ritter JM, Flower RJ. Rang and Dale\u2019s pharmacology. 6th ed. Philadelphia: Elsevier; 2007.","edition":"6"},{"issue":"2","key":"1548_CR3","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1213\/ANE.0b013e31823f0c28","volume":"115","author":"LJ Antonik","year":"2012","unstructured":"Antonik LJ, Goldwater DR, Kilpatrick GJ, Tilbrook GS, Borkett KM. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): part I. Safety, efficacy, and basic pharmacokinetics. Anesth Analg. 2012;115(2):274\u201383.","journal-title":"Anesth Analg"},{"key":"1548_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.690875","volume":"12","author":"GJ Kilpatrick","year":"2021","unstructured":"Kilpatrick GJ. Remimazolam: non-clinical and clinical profile of a new sedative\/anesthetic Aaent. Front Pharmacol. 2021;12: 690875.","journal-title":"Front Pharmacol"},{"key":"1548_CR5","unstructured":"US FDA. Byfavo\u00ae (remimazolam) for injection, for intravenous use, CIV Initial US Approval: 2020. 2023."},{"issue":"4","key":"1548_CR6","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00540-020-02755-1","volume":"34","author":"K Masui","year":"2020","unstructured":"Masui K. Remimazolam besilate, a benzodiazepine, has been approved for general anesthesia! J Anesth. 2020;34(4):479\u201382.","journal-title":"J Anesth"},{"key":"1548_CR7","unstructured":"European Medicines Agency. Byfavo. 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/byfavo. Accessed 30 Oct 2024."},{"key":"1548_CR8","unstructured":"PLC C. EndNote 21\u2122. 21.3 (Build 17918) ed. St. Helier, Sjersey: Clarivate\u2122; 2024."},{"key":"1548_CR9","unstructured":"DrugBAnk Online. Remimazolam: uses, interactions, mechanism of action. 24 Aug 2024. https:\/\/go.drugbank.com\/drugs\/DB12404. Accessed 30 Oct 2024."},{"key":"1548_CR10","unstructured":"European Medicines Agency. EMA summary of product characteristics (SmPC) Byfavo (remimazolam). 6 May 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/byfavo-epar-product-information_en.pdf. Accessed 11 Jun 2024."},{"key":"1548_CR11","unstructured":"MHRA. Public assessment report: national procedure: Byfavo 20mg powder for solution for injection remimazolam besylate PLGB 54212\/0001. 2021. https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/c71074a0d61f2f8f76ac9f046bee4b2b9e282899. Accessed 19 Nov 2024."},{"key":"1548_CR12","unstructured":"\u6bc5\u5cf0 Ngc-\u6797. YPSN202300028-N2(PPT).pdf - \u6ce8\u5c04\u7528\u7532\u82ef\u78fa\u9178\u745e\u9a6c\u5511\u4ed1 (\u745e\u500d\u5b81\u00ae). nhsa.gov.cn; 2023: p. 3. Accessed 13 Jul 2025."},{"key":"1548_CR13","unstructured":"Ltd JHPC. Hengrui pipeline: \u6052\u745e\u533b\u836f. https:\/\/www.hengrui.com\/en\/pipeline.html. Accessed 21 Aug 2024."},{"issue":"1","key":"1548_CR14","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1186\/s12871-024-02773-6","volume":"24","author":"H Zhang","year":"2024","unstructured":"Zhang H, Fu M, Yue F, Wei Y, Shi X, Yu S, Ji F. Comparison of the anesthetic effects of remimazolam tosilate and remimazolam besylate in daytime hysteroscopic surgery. BMC Anesthesiol. 2024;24(1):382.","journal-title":"BMC Anesthesiol"},{"key":"1548_CR15","unstructured":"MHRA. Summary of product characteristics. 30 Aug 2023. https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/d33377f81962ea12047c7c8e7fa4657a3c189f16. Accessed 19 Nov 2024."},{"issue":"4","key":"1548_CR16","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/anae.16205","volume":"79","author":"J Fechner","year":"2024","unstructured":"Fechner J, El-Boghdadly K, Spahn DR, Motsch J, Struys M, Duranteau O, et al. Anaesthetic efficacy and postinduction hypotension with remimazolam compared with propofol: a multicentre randomised controlled trial. Anaesthesia. 2024;79(4):410\u201322.","journal-title":"Anaesthesia"},{"issue":"4","key":"1548_CR17","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s00540-020-02776-w","volume":"34","author":"M Doi","year":"2020","unstructured":"Doi M, Hirata N, Suzuki T, Morisaki H, Morimatsu H, Sakamoto A. Safety and efficacy of remimazolam in induction and maintenance of general anesthesia in high-risk surgical patients (ASA Class III): results of a multicenter, randomized, double-blind, parallel-group comparative trial. J Anesth. 2020;34(4):491\u2013501.","journal-title":"J Anesth"},{"issue":"4","key":"1548_CR18","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s00540-020-02788-6","volume":"34","author":"M Doi","year":"2020","unstructured":"Doi M, Morita K, Takeda J, Sakamoto A, Yamakage M, Suzuki T. Efficacy and safety of remimazolam versus propofol for general anesthesia: a multicenter, single-blind, randomized, parallel-group, phase IIb\/III trial. J Anesth. 2020;34(4):543\u201353.","journal-title":"J Anesth"},{"issue":"6","key":"1548_CR19","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s40264-020-00914-7","volume":"43","author":"WJ Kim","year":"2020","unstructured":"Kim WJ, Li J, Oh I-S, Song I, Lee E, Namkoong K, Shin J-Y. Benzodiazepine use and risk of acute angle-closure glaucoma: a population-based case-crossover study. Drug Saf. 2020;43(6):539\u201347.","journal-title":"Drug Saf"},{"issue":"6","key":"1548_CR20","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s40265-020-01299-8","volume":"80","author":"SJ Keam","year":"2020","unstructured":"Keam SJ. Remimazolam: first approval. Drugs. 2020;80(6):625\u201333.","journal-title":"Drugs"},{"issue":"11","key":"1548_CR21","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1097\/EJA.0000000000001902","volume":"40","author":"S Kempenaers","year":"2023","unstructured":"Kempenaers S, Hansen TG, Van de Velde M. Remimazolam and serious adverse events: a scoping review. Eur J Anaesthesiol. 2023;40(11):841\u201353.","journal-title":"Eur J Anaesthesiol"},{"issue":"3","key":"1548_CR22","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.iac.2014.03.004","volume":"34","author":"GW Volcheck","year":"2014","unstructured":"Volcheck GW, Mertes PM. Local and general anesthetics immediate hypersensitivity reactions. Immunol Allergy Clin N Am. 2014;34(3):525\u201346.","journal-title":"Immunol Allergy Clin N Am"},{"issue":"1","key":"1548_CR23","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12871-023-02052-w","volume":"23","author":"X Hu","year":"2023","unstructured":"Hu X, Tang Y, Fang X. Laryngeal edema following remimazolam-induced anaphylaxis: a rare clinical manifestation. BMC Anesthesiol. 2023;23(1):99.","journal-title":"BMC Anesthesiol"},{"issue":"11","key":"1548_CR24","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1007\/s00228-020-02984-z","volume":"76","author":"M Pesic","year":"2020","unstructured":"Pesic M, Schippers F, Saunders R, Webster L, Donsbach M, Stoehr T. Pharmacokinetics and pharmacodynamics of intranasal remimazolam\u2014a randomized controlled clinical trial. Eur J Clin Pharmacol. 2020;76(11):1505\u201316.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"1548_CR25","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s40268-020-00317-0","volume":"20","author":"M Pesic","year":"2020","unstructured":"Pesic M, St\u00f6hr T, Ossig J, Borkett K, Donsbach M, Dao VA, et al. Remimazolam has low oral bioavailability and no potential for misuse in drug-facilitated sexual assaults, with or without alcohol: results from two randomised clinical trials. Drugs R D. 2020;20(3):267\u201377.","journal-title":"Drugs R D."},{"issue":"2","key":"1548_CR26","doi-asserted-by":"publisher","first-page":"164","DOI":"10.2174\/0113892002301026240318060307","volume":"25","author":"W Schmalix","year":"2024","unstructured":"Schmalix W, Petersen KU, Pesic M, Stohr T. The metabolism of the new benzodiazepine remimazolam. Curr Drug Metab. 2024;25(2):164\u201373.","journal-title":"Curr Drug Metab"},{"issue":"137","key":"1548_CR27","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jpba.2017.01.016","volume":"15","author":"Y Zhou","year":"2017","unstructured":"Zhou Y, Hu P, Jiang J. Metabolite characterization of a novel sedative drug, remimazolam in human plasma and urine using ultra high-performance liquid chromatography coupled with synapt high-definition mass spectrometry. J Pharm Biomed Anal. 2017;15(137):78\u201383.","journal-title":"J Pharm Biomed Anal"},{"issue":"3","key":"1548_CR28","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.bja.2021.05.027","volume":"127","author":"T St\u00f6hr","year":"2021","unstructured":"St\u00f6hr T, Colin PJ, Ossig J, Pesic M, Borkett K, Winkle P, et al. Pharmacokinetic properties of remimazolam in subjects with hepatic or renal impairment. Br J Anaesth. 2021;127(3):415\u201323.","journal-title":"Br J Anaesth"},{"issue":"4","key":"1548_CR29","doi-asserted-by":"publisher","first-page":"266","DOI":"10.2174\/0113892002300657240521094732","volume":"25","author":"KU Petersen","year":"2024","unstructured":"Petersen KU, Schmalix W, Pesic M, Stohr T. Drug-drug interaction potential of remimazolam: CYP 450, transporters, and protein binding. Curr Drug Metab. 2024;25(4):266\u201375.","journal-title":"Curr Drug Metab"},{"issue":"4","key":"1548_CR30","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1097\/ALN.0000000000003103","volume":"132","author":"J Sch\u00fcttler","year":"2020","unstructured":"Sch\u00fcttler J, Eisenried A, Lerch M, Fechner J, Jeleazcov C, Ihmsen H. Pharmacokinetics and pharmacodynamics of remimazolam (CNS 7056) after continuous infusion in healthy male volunteers: part I. Pharmacokinetics and clinical pharmacodynamics. Anesthesiology. 2020;132(4):636\u201351.","journal-title":"Anesthesiology"},{"issue":"2","key":"1548_CR31","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1213\/ANE.0b013e318241f68a","volume":"115","author":"HR Wiltshire","year":"2012","unstructured":"Wiltshire HR, Kilpatrick GJ, Tilbrook GS, Borkett KM. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): part II. Population pharmacokinetic and pharmacodynamic modeling and simulation. Anesth Analg. 2012;115(2):284\u201396.","journal-title":"Anesth Analg"},{"key":"1548_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinane.2020.109899","volume":"66","author":"J Zhou","year":"2020","unstructured":"Zhou J, Leonowens C, Ivaturi VD, Lohmer LL, Curd L, Ossig J, et al. Population pharmacokinetic\/pharmacodynamic modeling for remimazolam in the induction and maintenance of general anesthesia in healthy subjects and in surgical subjects. J Clin Anesth. 2020;66: 109899.","journal-title":"J Clin Anesth"},{"issue":"1","key":"1548_CR33","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/cts.12875","volume":"14","author":"J Zhou","year":"2021","unstructured":"Zhou J, Curd L, Lohmer LL, Ossig J, Schippers F, Stoehr T, et al. Population Pharmacokinetics of remimazolam in procedural sedation with nonhomogeneously mixed arterial and venous concentrations. Clin Transl Sci. 2021;14(1):326\u201334.","journal-title":"Clin Transl Sci"},{"issue":"4","key":"1548_CR34","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s00540-022-03079-y","volume":"36","author":"K Masui","year":"2022","unstructured":"Masui K, St\u00f6hr T, Pesic M, Tonai T. A population pharmacokinetic model of remimazolam for general anesthesia and consideration of remimazolam dose in clinical practice. J Anesth. 2022;36(4):493\u2013505.","journal-title":"J Anesth"},{"key":"1548_CR35","doi-asserted-by":"crossref","unstructured":"Eleveld DJ, Colin PJ, van den Berg JP, Koomen JV, Stoehr T, Struys MMRF. Covariate analysis of remimazolam pharmacokinetics and pharmacodynamics and proposed dosing and concentrations for anaesthesia and sedation. Br J Anaesth. 2025;135:206\u2013217.","DOI":"10.1016\/j.bja.2025.02.038"},{"issue":"6","key":"1548_CR36","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s00540-022-03099-8","volume":"36","author":"K Masui","year":"2022","unstructured":"Masui K, Hagihira S. Equilibration rate constant, k(e0), to determine effect-site concentration for the Masui remimazolam population pharmacokinetic model in general anesthesia patients. J Anesth. 2022;36(6):757\u201362.","journal-title":"J Anesth"},{"issue":"6","key":"1548_CR37","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s00540-022-03104-0","volume":"36","author":"K Masui","year":"2022","unstructured":"Masui K, Hagihira S. Correction: equilibration rate constant, k(e0), to determine effect-site concentration for the Masui remimazolam population pharmacokinetic model in general anesthesia patients. J Anesth. 2022;36(6):763.","journal-title":"J Anesth"},{"issue":"2","key":"1548_CR38","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1097\/ALN.0000000000004811","volume":"140","author":"R Vellinga","year":"2024","unstructured":"Vellinga R, Koomen JV, Eleveld DJ, St\u00f6hr T, Pesic M, Struys M, et al. Target-controlled infusion of remimazolam in healthy volunteers shows some acute tolerance. Anesthesiology. 2024;140(2):207\u201319.","journal-title":"Anesthesiology"},{"issue":"4","key":"1548_CR39","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1097\/ALN.0000000000003102","volume":"132","author":"A Eisenried","year":"2020","unstructured":"Eisenried A, Sch\u00fcttler J, Lerch M, Ihmsen H, Jeleazcov C. Pharmacokinetics and pharmacodynamics of remimazolam (CNS 7056) after continuous infusion in healthy male volunteers: part II. Pharmacodynamics of electroencephalogram effects. Anesthesiology. 2020;132(4):652\u201366.","journal-title":"Anesthesiology"},{"issue":"4","key":"1548_CR40","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1097\/ALN.0000000000005348","volume":"142","author":"R Vellinga","year":"2025","unstructured":"Vellinga R, Koomen JV, Eleveld DJ, Stohr T, Pesic M, Struys M, et al. Influence of remifentanil on the Pparmacokinetics and pharmacodynamics of remimazolam in healthy volunteers. Anesthesiology. 2025;142(4):666\u201379.","journal-title":"Anesthesiology"},{"issue":"10","key":"1548_CR41","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1111\/pan.14712","volume":"33","author":"M Bardol","year":"2023","unstructured":"Bardol M, Pan S, Walker SM, Standing JF, Dawes JM. Pharmacokinetic pharmacodynamic modeling of analgesics and sedatives in children. Paediatr Anaesth. 2023;33(10):781\u201392.","journal-title":"Paediatr Anaesth"},{"issue":"3","key":"1548_CR42","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s00228-019-02800-3","volume":"76","author":"XY Sheng","year":"2020","unstructured":"Sheng XY, Liang Y, Yang XY, Li LE, Ye X, Zhao X, et al. Safety, pharmacokinetic and pharmacodynamic properties of single ascending dose and continuous infusion of remimazolam besylate in healthy Chinese volunteers. Eur J Clin Pharmacol. 2020;76(3):383\u201391.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"1548_CR43","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/00004714-199008000-00003","volume":"10","author":"DA Chernik","year":"1990","unstructured":"Chernik DA, Gillings D, Laine H, Hendler J, Silver JM, Davidson AB, et al. Validity and reliability of the Observer\u2019s Assessment of Alertness\/Sedation scale: study with intravenous midazolam. J Clin Psychopharmacol. 1990;10(4):244\u201351.","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"1548_CR44","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1111\/cts.13023","volume":"14","author":"J Zhou","year":"2021","unstructured":"Zhou J, Curd L, Lohmer LRL, Delpratt N, Ossig J, Schippers F, et al. A population pharmacodynamic Markov mixed-effects model for determining remimazolam-induced sedation when co-administered with fentanyl in procedural sedation. Clin Transl Sci. 2021;14(4):1554\u201365.","journal-title":"Clin Transl Sci"},{"issue":"2","key":"1548_CR45","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/s00540-021-03030-7","volume":"36","author":"K Shirozu","year":"2022","unstructured":"Shirozu K, Nobukuni K, Tsumura S, Imura K, Nakashima K, Takamori S, et al. Neurological sedative indicators during general anesthesia with remimazolam. J Anesth. 2022;36(2):194\u2013200.","journal-title":"J Anesth"},{"issue":"5","key":"1548_CR46","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1213\/ANE.0b013e3182a705ae","volume":"117","author":"MT Worthington","year":"2013","unstructured":"Worthington MT, Antonik LJ, Goldwater DR, Lees JP, Wilhelm-Ogunbiyi K, Borkett KM, et al. A phase Ib, dose-finding study of multiple doses of remimazolam (CNS 7056) in volunteers undergoing colonoscopy. Anesth Analg. 2013;117(5):1093\u2013100.","journal-title":"Anesth Analg"},{"issue":"1","key":"1548_CR47","doi-asserted-by":"publisher","first-page":"9992","DOI":"10.1038\/s41598-023-37150-9","volume":"13","author":"BM Choi","year":"2023","unstructured":"Choi BM, Lee JS, Kim KM, Bang JY, Lee EK, Noh GJ. Frequency and characteristics of patients with bispectral index values of 60 or higher during the induction and maintenance of general anesthesia with remimazolam. Sci Rep. 2023;13(1):9992.","journal-title":"Sci Rep"},{"issue":"11","key":"1548_CR48","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1097\/EJA.0000000000001904","volume":"40","author":"KM Kim","year":"2023","unstructured":"Kim KM, Bang JY, Choi BM, Noh GJ. Assessment of explicit and implicit memories during remimazolam anaesthesia using the process dissociation procedure: a prospective cohort study. Eur J Anaesthesiol. 2023;40(11):833\u201340.","journal-title":"Eur J Anaesthesiol"},{"issue":"10","key":"1548_CR49","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1097\/EJA.0000000000002042","volume":"41","author":"EM Pereira","year":"2024","unstructured":"Pereira EM, Moraes VR, GayadaCosta M, Nascimento TSD, Slawka E, J\u00fanior CG, et al. Remimazolam vs. propofol for general anaesthesia in elderly patients: a meta-analysis with trial sequential analysis. Eur J Anaesthesiol. 2024;41(10):738\u201348.","journal-title":"Eur J Anaesthesiol"},{"issue":"1","key":"1548_CR50","doi-asserted-by":"publisher","first-page":"19022","DOI":"10.1038\/s41598-022-20946-6","volume":"12","author":"X Chen","year":"2022","unstructured":"Chen X, Zhang J, Yuan S, Huang H. Remimazolam besylate for the sedation of postoperative patients undergoing invasive mechanical ventilation in the ICU: a prospective dose-response study. Sci Rep. 2022;12(1):19022.","journal-title":"Sci Rep"},{"issue":"1","key":"1548_CR51","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.bja.2022.02.040","volume":"129","author":"D Chae","year":"2022","unstructured":"Chae D, Kim HC, Song Y, Choi YS, Han DW. Pharmacodynamic analysis of intravenous bolus remimazolam for loss of consciousness in patients undergoing general anaesthesia: a randomised, prospective, double-blind study. Br J Anaesth. 2022;129(1):49\u201357.","journal-title":"Br J Anaesth"},{"issue":"1","key":"1548_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00540-022-03107-x","volume":"37","author":"K Masui","year":"2023","unstructured":"Masui K. Caution! Reappearance of remimazolam effect after a flumazenil bolus: a larger bolus of flumazenil and a lower total remimazolam clearance are higher risks. J Anesth. 2023;37(1):1\u20135.","journal-title":"J Anesth"},{"issue":"1","key":"1548_CR53","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s00540-021-03021-8","volume":"36","author":"T Sato","year":"2022","unstructured":"Sato T, Nishiwaki K. Comparison of remimazolam and propofol in anesthetic management for awake craniotomy: a retrospective study. J Anesth. 2022;36(1):152\u20135.","journal-title":"J Anesth"},{"issue":"4","key":"1548_CR54","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.bja.2024.11.046","volume":"134","author":"S Komatsu","year":"2025","unstructured":"Komatsu S, Isogai T, Makito K, Matsui H, Fushimi K, Yasunaga H. Seizure after flumazenil reversal for total intravenous anaesthesia with remimazolam versus propofol: a matched retrospective cohort analysis of a large Japanese nationwide inpatient database. Br J Anaesth. 2025;134(4):1050\u20137.","journal-title":"Br J Anaesth"},{"issue":"4","key":"1548_CR55","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.bja.2023.07.004","volume":"131","author":"LA Evered","year":"2023","unstructured":"Evered LA, Pryor KO. Benzodiazepines and postoperative delirium: should we be as cautious as we are? Br J Anaesth. 2023;131(4):629\u201331.","journal-title":"Br J Anaesth"},{"key":"1548_CR56","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2147\/DDDT.S392569","volume":"17","author":"JJ Yang","year":"2023","unstructured":"Yang JJ, Lei L, Qiu D, Chen S, Xing LK, Zhao JW, et al. Effect of remimazolam on postoperative delirium in older adult patients undergoing orthopedic surgery: a prospective randomized controlled clinical trial. Drug Des Dev Ther. 2023;17:143\u201353.","journal-title":"Drug Des Dev Ther"},{"key":"1548_CR57","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.2147\/DDDT.S419146","volume":"17","author":"J Duan","year":"2023","unstructured":"Duan J, Ju X, Wang X, Liu N, Xu S, Wang S. Effects of remimazolam and propofol on emergence agitation in elderly patients undergoing hip replacement: a clinical, randomized, controlled study. Drug Des Dev Ther. 2023;17:2669\u201378.","journal-title":"Drug Des Dev Ther"},{"issue":"6","key":"1548_CR58","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1586\/17476348.2014.957186","volume":"8","author":"NT Vozoris","year":"2014","unstructured":"Vozoris NT. Do benzodiazepines contribute to respiratory problems? Expert Rev Respir Med. 2014;8(6):661\u20133.","journal-title":"Expert Rev Respir Med"},{"issue":"5","key":"1548_CR59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0268568","volume":"17","author":"Y Shimamoto","year":"2022","unstructured":"Shimamoto Y, Sanuki M, Kurita S, Ueki M, Kuwahara Y, Matsumoto A. Factors affecting prolonged time to extubation in patients given remimazolam. PLoS\u00a0One. 2022;17(5): e0268568.","journal-title":"PLoS\u00a0One"},{"issue":"6","key":"1548_CR60","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/j.bja.2024.02.005","volume":"132","author":"EC Barbosa","year":"2024","unstructured":"Barbosa EC, Espirito Santo PA, Baraldo S, Meine GC. Remimazolam versus propofol for sedation in gastrointestinal endoscopic procedures: a systematic review and meta-analysis. Br J Anaesth. 2024;132(6):1219\u201329.","journal-title":"Br J Anaesth"},{"issue":"1","key":"1548_CR61","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12871-024-02422-y","volume":"24","author":"X An","year":"2024","unstructured":"An X, Shen T, Yin X, Xu J, Zhang Y, Wang T. The safety of remimazolam versus propofol in gastroscopic sedation: a meta-analysis. BMC Anesthesiol. 2024;24(1):40.","journal-title":"BMC Anesthesiol"},{"issue":"3","key":"1548_CR62","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.gie.2018.04.2351","volume":"88","author":"DK Rex","year":"2018","unstructured":"Rex DK, Bhandari R, Desta T, DeMicco MP, Schaeffer C, Etzkorn K, et al. A phase III study evaluating the efficacy and safety of remimazolam (CNS 7056) compared with placebo and midazolam in patients undergoing colonoscopy. Gastrointest Endosc. 2018;88(3):427-37.e6.","journal-title":"Gastrointest Endosc"},{"issue":"1","key":"1548_CR63","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s40981-023-00638-4","volume":"9","author":"S Sekimoto","year":"2023","unstructured":"Sekimoto S, Kiyama S, Uezono S. Successful reversal of remimazolam anesthesia in a \u201ccannot intubate, can ventilate\u201d situation: a case report. JA Clin Rep. 2023;9(1):46.","journal-title":"JA Clin Rep."},{"issue":"1","key":"1548_CR64","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.bja.2024.04.020","volume":"133","author":"M Zhang","year":"2024","unstructured":"Zhang M, Liu H, Han X, Guo J, Ge Y. Reversing the triad of anaesthesia in a cannot intubate, cannot oxygenate emergency. Br J Anaesth. 2024;133(1):190\u20132.","journal-title":"Br J Anaesth"},{"key":"1548_CR65","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1007\/s40262-018-0672-3","volume":"57","author":"MM Sahinovic","year":"2018","unstructured":"Sahinovic MM, Struys MMRF, Absalom AR. Clinical pharmacokinetics and pharmacodynamics of propofol. Clin Pharmacokinet. 2018;57:1539\u201358.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1548_CR66","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/ACO.0000000000001384","volume":"37","author":"K Masui","year":"2024","unstructured":"Masui K. Remimazolam: its clinical pharmacology and evolving role in anesthesia and sedation practice. Curr Opin Anaesthesiol. 2024;37(4):344\u201351.","journal-title":"Curr Opin Anaesthesiol"},{"issue":"1","key":"1548_CR67","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/ANA.0000000000000975","volume":"37","author":"T Sato","year":"2025","unstructured":"Sato T, Ando T, Ozeki K, Asano I, Kuwatsuka Y, Ando M, et al. Prospective randomized controlled trial comparing anesthetic management with remimazolam besylate and flumazenil versus propofol during awake craniotomy following an asleep-awake-asleep method. J Neurosurg Anesthesiol. 2025;37(1):40\u20136.","journal-title":"J Neurosurg Anesthesiol"},{"issue":"2","key":"1548_CR68","doi-asserted-by":"publisher","first-page":"143","DOI":"10.4097\/kja.22441","volume":"76","author":"Y Suzuki","year":"2023","unstructured":"Suzuki Y, Kawashima S, Makino H, Doi M, Nakajima Y. Comparison of postoperative nausea and vomiting between remimazolam and propofol: a propensity score-matched, retrospective, observational, single-center cohort study. Korean J Anesthesiol. 2023;76(2):143\u201351.","journal-title":"Korean J Anesthesiol"},{"issue":"1","key":"1548_CR69","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12871-023-02091-3","volume":"23","author":"EJ Kim","year":"2023","unstructured":"Kim EJ, Kim CH, Yoon JY, Byeon GJ, Kim HY, Choi EJ. Comparison of postoperative nausea and vomiting between remimazolam and propofol in Patients undergoing oral and maxillofacial surgery: a prospective randomized controlled trial. BMC Anesthesiol. 2023;23(1):132.","journal-title":"BMC Anesthesiol"},{"issue":"5","key":"1548_CR70","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.bja.2023.08.019","volume":"131","author":"YQ Gao","year":"2023","unstructured":"Gao YQ, Ihmsen H, Hu ZY, Sun W, Fang YB, Wang Z, et al. Pharmacokinetics of remimazolam after intravenous infusion in anaesthetised children. Br J Anaesth. 2023;131(5):914\u201320.","journal-title":"Br J Anaesth"},{"issue":"4","key":"1548_CR71","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1213\/ANE.0000000000000814","volume":"121","author":"MA Bj\u00f6rnsson","year":"2015","unstructured":"Bj\u00f6rnsson MA, Norberg \u00c5, Kalman S, Simonsson USH. A recirculatory model for pharmacokinetics and the effects on Bispectral Index after intravenous infusion of the sedative and anesthetic AZD3043 in healthy volunteers. Anesth Analg. 2015;121(4):904\u201313.","journal-title":"Anesth Analg"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01548-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01548-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01548-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T23:16:43Z","timestamp":1757459803000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01548-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":71,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1548"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01548-7","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,21]]},"assertion":[{"value":"6 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was solely supported by departmental funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Bas T. de Jong has no conflicts of interest that are directly relevant to the content of this article. For departmental conflicts of interest, see MMRFS. Douglas J. Eleveld has no conflicts of interest that are directly relevant to the content of this article. For departmental conflicts of interest, see MMRFS. Keira P. Mason: her research group has received funding for sponsor-initiated research from Eagle Pharmaceuticals Inc., Woodcliff Lake, NJ, USA. Michel M.R.F. Struys: his research group\/department received (over the last 3 years) research grants and consultancy fees from Masimo (Irvine, CA, USA), Becton Dickinson (Eysins, Switzerland), Fresenius-Kabi (Bad Homburg, Germany), Paion (Aachen, Germany), Medcaptain Europe (Andelst, The Netherlands), Baxter (Chicago, IL, USA), Eagle Pharmaceuticals Inc. (Woodcliff, NJ, USA) and HanaPharm (Seoul, Republic of Korea). He receives royalties on intellectual property from Demed Medical (Sinaai, Belgium) and Ghent University (Ghent, Belgium).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"BTdJ: literature search, conceptualization, and writing. DJE: writing sections, manuscript correction. KPM: writing sections, literature search, manuscript correction. MMRFS: conceptualization, writing sections, manuscript correction.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}